Alejandro Martín
Director General of Mexico and LATAM DIrector
Mayoly Spindler
View from the Top

Mayoly Splinder Out to Conquer Gastroenterology

Wed, 09/07/2016 - 09:55

Q: Can you give us a brief overview of Mayoly Spindler’s history in Mexico?
A: The company has been present in the Mexican market for over 10 years, commercializing solutions to frequent gastroenterology ailments such as irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), functional constipation and diarrhea. Meteospasmyl® is one of the company’s blockbusters prescribed for IBS treatment. It is a soft gel presentation of alverine and simethicone compounds. Mayoly Spindler’s manufacturing plant is the best equipped for soft gel creation, further positioning it as segment leader. IPRIKENE®, on the other hand, is a natural clay called diosmectite that is effective as a treatment for diarrhea, considering it combats toxins, viruses and bacteria.

Q: Considering diarrheic conditions account for one of the government’s biggest healthcare expenditures, what measures has the company taken in this regard?
A: Diarrhea is the second cause of infant mortality in Mexico. Therefore, supplying governmental institutions that lack complementary adjuvants for oral rehydration with our products is of the utmost importance. Mayoly Spindler’s diosmectite clay is the only antidiarrheal authorized for consumption in 1 month-old infants.

IBS is a hypersensitive chronic condition correlated to abdominal pain, and distension or inflammation, which has a direct impact on a patient’s bowel evacuation habits. The most common manifestations of IBS are diarrhea, constipation or a combination of both. Even though the ailment has no present cure it can be controlled with the right medication. The use of Meteospasmyl®, coupled with probiotics can help minimize symptoms. Probiotics are booming in Mexico. Mayoly Spindler’s Progiolog® is developed with two of the most thoroughly studied strains Lactobacillus acidophilus and Bifidobacterium lactis, which recolonize intestinal microbiota. Regular use of Progiolog® is beneficial for users.

Q: What partnerships has the company created to broaden its market presence?
A: Mayoly Spindler can be found in multiple decentralized public organs, such as Chihuahua’s Civil Pensions, Guadalajara’s Civil Hospitals and Sonora’s Institute for Social Security and Services for State Workers (ISSSTESON). In addition, we partially participate with the Ministry of National Defense (SEDENA) and PEMEX. We are convinced that our alternative treatments have an enormous social impact and will soon grow our relationships with centralized public organs.

Q: What growth has the company seen over the last couple of years?
A: Mayoly Spindler has seen sustained growth in its 10- year presence in Mexico. We even achieved double digit growth during the tough years of 2014 and 2015. Due to the extraordinary acceptance our products have had, we slightly surpassed the 20 percent mark. In 2015 the health industry grew by 6 to 11 percent while Mayoly Spindler achieved 30 percent growth. On average the company’s market share is 17.2 percent. We hold the 23rd position in a growing Rx segment that evaluates a total of 156 laboratories. We expect to improve our position by at least three slots by the end of 2016.

Q: What type of product portfolio expansions is the company foreseeing in the mid-term?
A: We foresee 19 product releases over the next five years averaging three per year. Our goal is to become leaders in the gastroenterology segment and our focus and efforts will remain confined to those markets. Mexico has become a reference for Mayoly Spindler worldwide as operations have maintained an optimal performance since their establishment. Mayoly Spindler’s Mexican division now oversees all Latin American operations and it saw 40 percent growth at the close of 2015, the biggest of the company.